Roger Jeffs

 
Academic Background
 

Dr. Roger Jeffs is a prominent figure in the biopharmaceutical industry with a rich and varied career spanning several decades. His journey began academically with a Bachelor's degree in Chemistry from Duke University, which he earned between 1980 and 1984. He furthered his education with a PhD in Pharmacology from the UNC School of Medicine, completed in 1991.

 
Early Career
 

Dr. Jeffs has held numerous prominent positions throughout his career, each contributing to his reputation as a leader and innovator in biopharmaceuticals. Early in his career, he worked as a Technical Consultant for Biotech/Pharma Patent Prosecution & Litigation at Cusham Darby & Cushman and a Clinical Research Scientist at Burroughs Wellcome. His role as Associate Director of Product Development at Amgen between 1995 and 1998 marked his first significant leadership position in the industry.

 
United Therapeutics Corporation
 

One of his most notable achievements was his extensive tenure at United Therapeutics Corporation, where he served from 1998 to 2016 in various capacities, including President, COO, and later as co-CEO. During his time at United Therapeutics, Dr. Jeffs oversaw critical milestones, including the initial public offering (IPO) and the clinical development of six rare disease products, underscoring his impact on the company's growth and innovative direction.

 
Board Memberships
 

Following this, Dr. Jeffs expanded his influence by taking on board member roles at several companies, including Dova Pharmaceuticals, Sangamo Therapeutics, Axovant Sciences, SPYRYX Biosciences, and others. His strategic insights were sought after by many in the industry, leading him to influence multiple biopharmaceutical ventures.

 
Current Positions
 

Currently, Dr. Jeffs holds several key positions. He is the CEO at Liquidia Corporation since January 2022, focusing on pioneering therapies for pulmonary hypertension. Additionally, he is the Vice-Chairman and Co-founder of Kryia Therapeutics, which aims to accelerate gene therapy development. He also co-founded and owns Bull City Select Investments, showcasing his entrepreneurial spirit.

 
Awards and Recognitions
 

Dr. Jeffs's achievements have not gone unnoticed. He was honored with the 2015 Wings of Hope Award from Solving Kids’ Cancer, recognizing his efforts in advancing cancer research and his dedication to children's health.

 
Career Highlights
 

Dr. Jeffs's career is marked by his steadfast leadership, innovative vision, and significant contributions to the biopharmaceutical industry. His work continues to push the boundaries of medical research and biopharmaceutical development, making lasting impacts on the industry and patients' lives.